Safety of Percutaneous Dilatational Tracheotomy in Patients on Dual Antiplatelet Therapy and Anticoagulation

• Published in: Critical care explorations 2019-10, Vol.1 (10), p.e0050-e0050
• Main Authors: Lüsebrink, Enzo, Stark, Konstantin, Bertlich, Mattis, Kupka, Danny, Stremmel, Christopher, Scherer, Clemens, Stocker, Thomas J, Orban, Mathias, Petzold, Tobias, Kneidinger, Nikolaus, Stemmler, Hans-Joachim, Massberg, Steffen, Orban, Martin
• Format: Article
• Language: English
• Subjects: Original Clinical Report
• ISSN: 2639-8028; 2639-8028
• DOI: 10.1097/CCE.0000000000000050

Percutaneous dilatational tracheotomy has become a routine procedure in ICUs. However, given the high and steadily growing number of patients receiving anticoagulation, dual antiplatelet therapy, or even a combination of both (also known as "triple therapy"), there are concerns about the safety of the procedure, in particular for critically ill patients with a high risk of bleeding. In this retrospective study, we investigated whether percutaneous dilatational tracheotomy in this high-risk population was associated with elevated procedural complications. Retrospective single-center study with analysis of all percutaneous dilatational tracheotomies performed in our cardiac ICU from January 2018 to May 2019. Munich university hospital's cardiac ICU. A total of 34 patients who underwent percutaneous dilatational tracheotomy according to Ciaglia technique with accompanying bronchoscopy in our cardiac ICU from January 2018 to May 2019 were included. Patients were stratified into clinically relevant risk groups based on anticoagulation and antiplatelet therapy considering standard laboratory coagulation parameters, that is, activated partial thromboplastin time, international normalized ratio, and platelet count with differentiated analysis of procedure-related complications in each risk group until hospital discharge. A total of 34 patients who underwent percutaneous dilatational tracheotomy were included and assigned to five clinically relevant treatment groups: IV unfractionated heparin (prophylactic dosage) ( = 4), IV unfractionated heparin (therapeutic dosage) ( = 4), aspirin and IV unfractionated heparin (therapeutic dosage) ( = 7), dual antiplatelet therapy with IV unfractionated heparin (prophylactic dosage) ( = 5), and dual antiplatelet therapy with IV unfractionated heparin (therapeutic dosage) ( = 14). Three bleedings without surgical intervention or blood transfusion were documented in the whole cohort, but no single bleeding did occur in the triple therapy group. These were exclusively caused by skin bleedings at the immediate puncture site-each of which could be easily treated with one or two single stitches. There were no severe bleeding complications or potentially life-threatening procedure-related complications. Additionally, the rate of complications in patients with elevated body mass index was not increased. Bronchoscopy-guided percutaneous dilatational tracheotomy according to Ciaglia technique with careful consideration of all potential in